Benzinga | Sep 15, 2021 11:01AM EDT

Oragenics Launches Animal Study For COVID-19 Vaccine Candidate

* Oragenics Inc (NYSE:OGEN) has initiated a hamster challenge study to evaluate the immunogenicity and viral load reduction impact of its COVID-19 vaccine candidate.

* Related Content: Oragenics's New Preclinical Data Supports Its Approach For COVID-19 Vaccine Development.

* The study will provide data for several vaccine formulations, using adjuvants specific for both intranasal and intramuscular routes of administration.

* An assessment of cross-neutralization titers against the Wuhan, Beta, and Delta variants of COVID-19 and reduction in the viral load of the Wuhan challenge virus will be used to establish the most promising formulations to advance to human clinical studies.

* The study is being conducted by the Company's Canadian collaborator, with results expected in November.

* Price Action: OGEN stock is down 1.54% at $0.64 during the market session on the last check Wednesday.